Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 16INDUSTRY 7NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Recurrent Squamous Cell Lung Carcinoma 3Prostatic Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Malignancies 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Cancer Metastatic 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Advanced Rare Tumours 1

Interventions

Cyclophosphamide 2palbociclib 1olaparib 1fludarabine 1durvalumab 1binimetinib 1atezolizumab 1Methotrexate 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Triple Negative Breast Neoplasms × durvalumab × Clear all
NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡